0001437749-26-009059
SEC filingEton Pharmaceuticals, Inc. reported strong revenue growth in FY 2025, with total net revenues reaching $80.0 million, up 105% from $39.0 million in 2024, driven by increased product sales and royalties of $76.7 million (up from $38.5 million) from key products like INCRELEX, ALKINDI SPRINKLE, and GALZIN, plus licensing revenue of $3.3 million (up from $0.5 million). Gross profit rose 83% to $42.7 million, though gross margin dipped to 53.5% from 60.0% due to higher commissions on out-licensing. Operating expenses increased to $43.6 million (R&D $7.8 million, G&A $35.8 million), leading to a $844K operating loss, improved from $2.6 million loss prior year. Net loss widened slightly to $4.6 million ($-0.17 per share) from $3.8 million ($-0.15 per share), impacted by $3.7 million interest expense. Balance sheet strengthened with $92.1 million total assets, $25.9 million cash, and $26.2 million equity. Operating cash flow surged to $10.5 million from $1.0 million, supporting $11.0 million cash increase. The company maintains liquidity for 12+ months, focusing on rare disease portfolio expansion amid pipeline progress like ET-600 PDUFA in 2026.
Eton Pharmaceuticals delivered robust top-line growth in FY 2025, with total net revenues of $80.0 million, a 105% increase from $39.0 million in 2024. Product sales and royalties net reached $76.7 million (up $38.2 million YoY), fueled by higher volumes of INCRELEX (acquired Dec 2024), ALKINDI SPRINKLE, and GALZIN (commercialized Mar 2025). Licensing revenue rose to $3.3 million from $0.5 million, including $1.8 million from INCRELEX ex-US out-licensing and $1.5 million DS-200 milestone. Gross profit grew 83% to $42.7 million, but margin contracted to 53.5% from 60.0% due to elevated commissions. Operating loss narrowed to $844K from $2.6 million, despite R&D up 136% to $7.8 million (ET-600 NDA fee) and G&A up 57% to $35.8 million (marketing, headcount). Net loss was $4.6 million (-$0.17/share) vs $3.8 million prior, with interest expense at $3.7 million. Cash flow from operations jumped to $10.5 million from $1.0 million.
Revenues were dominated by product sales and royalties at $76.7 million (96% of total), up 99% YoY from $38.5 million, primarily from INCRELEX, ALKINDI SPRINKLE, and GALZIN launches/acquisitions in late 2024. Licensing contributed $3.3 million (4%), boosted by INCRELEX ex-US rights ($1.8 million) and DS-200 milestone ($1.5 million). All revenues from U.S. operations except minor foreign licensing. No geographic breakdown beyond U.S. dominance. Growth reflects commercial execution in rare diseases (endocrinology, metabolic), with eight commercial products and pipeline advancements like KHINDIVI (approved May 2025).
Gross margin declined to 53.5% from 60.0% as cost of sales rose 138% to $37.2 million, driven by higher product volumes, INCRELEX commissions, and $5.1 million inventory step-up. Operating margin improved slightly to -1.1% from -6.7%, with expenses up 67% to $43.6 million (R&D +$4.5 million, G&A +$13.0 million). Adjusted EBITDA turned positive at $15.8 million from $2.9 million, excluding stock comp ($5.5 million), amortization ($4.0 million), and step-up. Non-GAAP net income $10.8 million ($0.32 diluted EPS).
Operating cash flow surged to $10.5 million (from $1.0 million), aided by $6.4 million AR collection, $6.8 million AP increase, despite inventory build. Investing outflow minimal at $333K (PPE). Financing provided $815K (stock exercises, ESPP). Cash rose $11.0 million to $25.9 million; total current assets $60.6 million, working capital $22.1 million. Debt $30.6 million net (SWK facility, SOFR+6.75%, matures 2027). Total assets $92.1 million (intangibles $30.9 million), liabilities $66.0 million, equity $26.2 million. Liquidity sufficient for 12+ months.
Management expects revenues and cash flows from portfolio to fund operations 12+ months, with growth from market penetration and launches (ET-600 PDUFA Feb 2026, KHINDIVI, GALZIN). Pipeline includes Amglidia, ET-700/800, ZENEO. Risks: IRA/Medicare pricing, rebates, competition, regulatory delays, debt covenants. Focus on rare diseases via acquisitions, 505(b)(2) pathway; 44 employees (12 R&D, 24 sales/marketing).